deferoxamine has been researched along with Stunted Growth in 25 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The severe toxic effects on vision, hearing and growth are all more likely at higher doses of DF and there appears to be partial protection against them by iron overload." | 2.38 | The toxic effects of desferrioxamine. ( Huehns, ER; Porter, JB, 1989) |
| "Hypogonadism was noted in 59% of the patients who reached pubertal age, and short stature was found in 36% of patients who reached final height." | 1.33 | Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. ( Carmi, D; Kornreich, L; Miskin, H; Phillip, M; Shalitin, S; Tamary, H; Weintrob, N; Yaniv, I; Zilber, R, 2005) |
| "Dental caries were significantly higher in thalassemics." | 1.33 | Physical growth patterns and dental caries in thalassemia. ( Dewan, P; Gomber, S, 2006) |
| "A male thalassemia major patient who developed bone and cartilage abnormalities with a standard dose of desferrioxamine (DFX) given subcutaneously from the age of 4 years was treated with the oral iron chelator deferiprone (L1)." | 1.31 | Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine. ( Campisi, S; De Sanctis, V; Di Silvestro, G; Mangiagli, A; Urso, L, 2000) |
| "Since patients with thalassemia are not growth hormone deficient, the data suggest the possibility of defective hepatic biosynthesis of somatomedin." | 1.26 | Depressed serum somatomedin activity in beta-thalassemia. ( Graziano, JH; Hilgartner, MW; Levine, LS; Markenson, AL; New, MI; Saenger, P; Schwartz, E, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (48.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shalitin, S | 1 |
| Carmi, D | 1 |
| Weintrob, N | 1 |
| Phillip, M | 1 |
| Miskin, H | 1 |
| Kornreich, L | 1 |
| Zilber, R | 1 |
| Yaniv, I | 1 |
| Tamary, H | 1 |
| Gomber, S | 1 |
| Dewan, P | 1 |
| Pomarède, R | 1 |
| Girot, R | 1 |
| Constant, S | 1 |
| Rappaport, R | 1 |
| Ley, TJ | 1 |
| Griffith, P | 1 |
| Nienhuis, AW | 1 |
| Saenger, P | 1 |
| Schwartz, E | 1 |
| Markenson, AL | 1 |
| Graziano, JH | 1 |
| Levine, LS | 1 |
| New, MI | 1 |
| Hilgartner, MW | 1 |
| Borgna-Pignatti, C | 2 |
| Zurlo, MG | 1 |
| DeStefano, P | 1 |
| Boffa, C | 1 |
| DeSanctis, V | 1 |
| DiPalma, A | 1 |
| DiGregorio, L | 1 |
| Melevendi, C | 2 |
| Piga, A | 2 |
| Sabato, V | 1 |
| Giardina, PJ | 1 |
| Grady, RW | 1 |
| Albo, C | 1 |
| Cabrera, J | 1 |
| Dios, A | 1 |
| Castro, M | 1 |
| Ares, C | 1 |
| Constenla, I | 1 |
| López, D | 1 |
| Naselli, A | 2 |
| Vignolo, M | 1 |
| Di Battista, E | 1 |
| Garzia, P | 1 |
| Forni, GL | 1 |
| Traverso, T | 1 |
| Aicardi, G | 1 |
| Cavallo, L | 1 |
| Gurrado, R | 1 |
| Zecchino, C | 1 |
| Manolo, F | 1 |
| De Sanctis, V | 3 |
| Cisternino, M | 1 |
| Caruso-Nicoletti, M | 2 |
| Galati, M | 1 |
| Di Bella, D | 1 |
| Pizzarelli, G | 1 |
| Leonardi, C | 1 |
| Sciuto, C | 1 |
| Coco, M | 1 |
| Di Gregorio, F | 1 |
| Mangiagli, A | 1 |
| Campisi, S | 1 |
| Di Silvestro, G | 1 |
| Urso, L | 1 |
| Taher, A | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Inati, A | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Viprakasit, V | 1 |
| Tanphaichitr, VS | 1 |
| Mahasandana, C | 1 |
| Assteerawatt, A | 1 |
| Suwantol, L | 1 |
| Veerakul, G | 1 |
| Kankirawatana, S | 1 |
| Pung-Amritt, P | 1 |
| Suvatte, V | 1 |
| Cividalli, G | 1 |
| O'Brien, RT | 2 |
| Pearson, HA | 1 |
| Orzincolo, C | 1 |
| Scutellari, PN | 1 |
| Castaldi, G | 1 |
| Davies, SC | 1 |
| Wonke, B | 1 |
| Porter, JB | 1 |
| Huehns, ER | 1 |
| De Virgiliis, S | 1 |
| Congia, M | 1 |
| Frau, F | 1 |
| Argiolu, F | 1 |
| Diana, G | 1 |
| Cucca, F | 1 |
| Varsi, A | 1 |
| Sanna, G | 1 |
| Podda, G | 1 |
| Fodde, M | 1 |
| Luzzatto, L | 1 |
| Capalbo, P | 1 |
| Gambotto, S | 1 |
| Tricta, F | 1 |
| Gabutti, V | 2 |
| Festa, RS | 1 |
| De Stefano, P | 1 |
| Zonta, L | 1 |
| Vullo, C | 1 |
| Masera, G | 1 |
| Terzoli, S | 1 |
| Wolman, IJ | 1 |
| Ortolani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for deferoxamine and Stunted Growth
| Article | Year |
|---|---|
Transfusion haemosiderosis and chelation therapy.
Topics: Adolescent; Adult; Ascorbic Acid; Blood Transfusion; Cardiomyopathies; Deferoxamine; Dose-Response R | 1982 |
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
Iron overload: clinical and pathologic aspects in pediatrics.
Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr | 1977 |
The management of haemoglobinopathies.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc | 1991 |
The toxic effects of desferrioxamine.
Topics: Animals; Blood-Brain Barrier; Deferoxamine; Disease Susceptibility; Eye Diseases; Growth Disorders; | 1989 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
1 trial available for deferoxamine and Stunted Growth
| Article | Year |
|---|---|
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
18 other studies available for deferoxamine and Stunted Growth
| Article | Year |
|---|---|
Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Body Height; Child; Child, Preschool; Deferoxamine; | 2005 |
Physical growth patterns and dental caries in thalassemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Deferoxamine; Dental Caries; Female; Ferrit | 2006 |
[Effect of hematologic treatment on the growth and puberty of children with thalassemia major].
Topics: Adolescent; Blood Transfusion; Body Height; Child; Combined Modality Therapy; Deferoxamine; Female; | 1984 |
Depressed serum somatomedin activity in beta-thalassemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Female; Growth Disorders; Hemosiderosis; H | 1980 |
Outcome of thalassemia treated with conventional therapy.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Cardiovascular Diseases; Cause of Death; Chelation | 1993 |
[Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1995 |
Long-term follow-up of skeletal dysplasia in thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Body Height; Bone Diseases, Developmental; D | 1998 |
Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
Topics: Adolescent; Age Determination by Skeleton; beta-Thalassemia; Blood Transfusion; Body Height; Child; | 1998 |
Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
Topics: beta-Thalassemia; Blood Transfusion; Bone Diseases; Chelating Agents; Child; Deferoxamine; Female; G | 1998 |
Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
Topics: beta-Thalassemia; Body Height; Bone Diseases; Deferiprone; Deferoxamine; Growth Disorders; Humans; I | 2000 |
Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
Topics: beta-Thalassemia; Blood Transfusion; Body Height; Body Weight; Chi-Square Distribution; Child; Defer | 2001 |
The clinical management of homozygous beta-thalassemia.
Topics: Blood Transfusion; Deferoxamine; Endocrine System Diseases; Growth Disorders; Humans; Splenectomy; T | 1979 |
The management of thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Diet | 1975 |
Growth plate injury of the long bones in treated beta-thalassemia.
Topics: Adolescent; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Female; Follow-Up Studies; Gro | 1992 |
Deferoxamine-induced growth retardation in patients with thalassemia major.
Topics: Body Height; Bone and Bones; Deferoxamine; Dose-Response Relationship, Drug; Female; Growth Disorder | 1988 |
High-dose desferrioxamine as a cause of growth failure in thalassemic patients.
Topics: Child; Child, Preschool; Deferoxamine; Female; Ferritins; Growth Disorders; Humans; Male; Thalassemi | 1988 |
Growth and sexual maturation in thalassemia major.
Topics: Adolescent; Adult; Age Determination by Skeleton; Amenorrhea; Blood Transfusion; Body Height; Child; | 1985 |
Some clinical features of Cooley's anemia patients as related to transfusion schedules.
Topics: Blood Transfusion; Deferoxamine; Fetal Hemoglobin; Growth Disorders; Hematopoiesis; Humans; Iron; Li | 1969 |